Monitoring the immune response of anti-SARS-CoV2 vaccinated individuals and COVID-19-positive patients – a prospective monocentric non-interventional observational study

Monitoring the immune response of anti-SARS-CoV2 vaccinated individuals and COVID-19-positive patients – a prospective monocentric non-interventional observational study - Immu-COVID-19-SKD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024551

Enrollment

700

Registered

2021-03-08

Start date

2021-03-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1 U08.9

Interventions

Group 1: COVID-19 patients in the Dessau Medical Center Group 2: Anti-SARS-CoV2 vaccinated persons at the Dessau Medical Center (staff) Group 3: Anti-SARS-CoV2 vaccinated hemato-oncolological patients

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Employees of the Dessau Medical Center, COVID-19 patients of the Dessau Medical Center, hemato-oncological patients of the Dessau Medical Center

Exclusion criteria

Exclusion criteria: Persons, who do not confirm their participation at the study

Design outcomes

Primary

Measure	Time frame
SARS-CoV2 antibody titre in serum - blood collection 2, 4, 8 12, 16, 32, 48 weeks after the second vaccination	—

Secondary

Measure	Time frame
Blood count, CRP, BSG, C3, C4, circulating immune complexes, IL-6, IL-2 receptor, TNF-a, IL-4, IL-13 through blood control 2, 4, 8 12, 16, 32, 48 weeks after the second vaccination General symptoms, dermatological findings 2, 4, 8 12, 16, 32, 48 weeks after the second vaccination in the staff and the dermato-oncological patients of the Dessau Medical Center General symptoms, dermatological findings during COVID-19 infection and 2, 4, 8 12, 16, 32, 48 weeks after infection detection in COVID-19 patients of the Dessau Medical Center	—

Measure

Time frame

Blood count, CRP, BSG, C3, C4, circulating immune complexes, IL-6, IL-2 receptor, TNF-a, IL-4, IL-13 through blood control 2, 4, 8 12, 16, 32, 48 weeks after the second vaccination General symptoms, dermatological findings 2, 4, 8 12, 16, 32, 48 weeks after the second vaccination in the staff and the dermato-oncological patients of the Dessau Medical Center General symptoms, dermatological findings during COVID-19 infection and 2, 4, 8 12, 16, 32, 48 weeks after infection detection in COVID-19 patients of the Dessau Medical Center

—

Countries

Germany

Contacts

Public ContactSabine Westphal

Institut für Klinische Chemie und Laboratoriumsdiagnostik, Städtisches Klinikum Dessau

franka.bohle@klinikum-dessau.de49-340-5014880

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026